Top

Published in:

01-03-2016 | Breast Oncology

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

Authors: B. Schaefgen, M. Mati, H. P. Sinn, MD, M. Golatta, MD, A. Stieber, MD, G. Rauch, PhD, A. Hennigs, MD, H. Richter, C. Domschke, MD, F. Schuetz, MD, C. Sohn, MD, A. Schneeweiss, MD, Joerg Heil, MD

Published in: Annals of Surgical Oncology | Issue 3/2016

Abstract

Background

This study evaluated breast imaging procedures for predicting pathologic complete response (pCR = ypT0) after neoadjuvant chemotherapy (NACT) for breast cancer to challenge surgery as a diagnostic procedure after NACT.

Methods

This retrospective, exploratory, monocenter study included 150 invasive breast cancers treated by NACT. The patients received magnetic resonance imaging (MRI), mammography (MGR), and ultrasound (US). The results were classified in three response subgroups according to response evaluation criteria in solid tumors. To incorporate specific features of MRI and MGR, an additional category [clinical near complete response (near-cCR)] was defined. Residual cancer in imaging and pathology was defined as a positive result. Negative predictive values (NPVs), false-negative rates (FNRs), and false-positive rates (FPRs) of all imaging procedures were analyzed for the whole cohort and for triple-negative (TN), HER2-positive (HER2+), and HER2-negative/hormone-receptor-positive (HER2−/HR+) cancers, respectively.

Results

In 46 cases (31 %), pCR (ypT0) was achieved. Clinical complete response (cCR) and near-cCR showed nearly the same NPVs and FNRs. The NPV was highest with 61 % for near-cCR in MRI and lowest with 44 % for near-cCR in MGR for the whole cohort. The FNRs ranged from 4 to 25 % according to different imaging methods. The MRI performance seemed to be superior, especially in TN cancers (NPV 94 %; FNR 5 %). The lowest FPR was 10 % in MRI, and the highest FPR was 44 % in US.

Conclusion

Neither MRI nor MGR or US can diagnose a pCR (ypT0) with sufficient accuracy to replace pathologic diagnosis of the surgical excision specimen.

Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the national cancer database. J Am Coll Surg. 2015;220:1063–9. doi:10.1016/j.jamcollsurg.2015.02.011.CrossRefPubMed

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.PubMed

Von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100:552–62. doi:10.1093/jnci/djn089.CrossRef

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804. doi:10.1200/JCO.2011.38.8595.CrossRef

Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–27. doi:10.1200/jco.2005.04.1665.CrossRefPubMed

Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46:1296–316. doi:10.1016/j.ejca.2010.02.015.CrossRefPubMed

Heys SD, Chaturvedi S. Primary chemotherapy in breast cancer: the beginning of the end or the end of the beginning for the surgical oncologist? World J Surg Oncol. 2003;1:14. doi:10.1186/1477-7819-1-14.PubMedCentralCrossRefPubMed

Rea D, Tomlins A, Francis A. Time to stop operating on breast cancer patients with pathological complete response? Eur J Surg Oncol. 2013;39:924–30. doi:10.1016/j.ejso.2013.06.005.CrossRefPubMed

Mamounas EP. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol. 2015;22:1425–33. doi:10.1245/s10434-015-4406-6.CrossRefPubMed

10.

Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21, and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer. 2007;7:36. doi:10.1186/1471-2407-7-36.PubMedCentralCrossRefPubMed

11.

Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007;110:1687–96. doi:10.1002/cncr.22981.CrossRefPubMed

12.

Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265–77. doi:10.1200/JCO.2005.02.0818.CrossRefPubMed

13.

Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257–64. doi:10.1097/01.sla.0000197714.14318.6f.PubMedCentralCrossRefPubMed

14.

Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.CrossRefPubMed

15.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed

16.

Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Instit. 2013;105:321–33. doi:10.1093/jnci/djs528.CrossRef

17.

National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment (NICE Clinical Guidelines, no. 80.). National Collaborating Centre for Cancer (UK), Cardiff, 2009.

18.

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2011. doi:10.1245/s10434-011-2108-2.PubMed

19.

Senn H. St. Gallen consensus 2013: optimizing and personalizing primary curative therapy of breast cancer worldwide. Breast Care Basel Switzerland. 2013;8:101. doi:10.1159/000351222.CrossRef

20.

Wockel A, Kreienberg R. First revision of the German S3 Guideline “diagnosis, therapy, and follow-up of breast cancer.” Breast Care. 2008;3:82–6. doi:10.1159/000127509.PubMedCentralCrossRefPubMed

21.

Lebeau A, Kreipe H, Dietel M, Schlake W, Kreienberg R. Breast cancer: current recommendations for pathologists on the basis of the S3 guidelines. Der Pathol. 2013;34:293–302; quiz 303–4. doi:10.1007/s00292-013-1763-4.CrossRef

22.

Heil J, Buehler A, Golatta M, Rom J, Schipp A, Harcos A et al. Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI? Ann Oncol. 2012;23:98–104. doi:10.1093/annonc/mdr064.CrossRefPubMed

23.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7–18.CrossRefPubMed

24.

Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22:1416–24. doi:10.1245/s10434-015-4403-9.CrossRefPubMed

25.

McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18:3149–54. doi:10.1245/s10434-011-1912-z.CrossRefPubMed

26.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119:1776–83. doi:10.1002/cncr.27995.CrossRef

27.

Ciatto S, Houssami N, Apruzzese A, Bassetti E, Brancato B, Carozzi F, et al. Reader variability in reporting breast imaging according to BI-RADS assessment categories (the Florence experience. Breast Edinburgh Scotland. 2006;15:44–51. doi:10.1016/j.breast.2005.04.019.CrossRef

Title: Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
Authors: B. Schaefgen
M. Mati
H. P. Sinn, MD
M. Golatta, MD
A. Stieber, MD
G. Rauch, PhD
A. Hennigs, MD
H. Richter
C. Domschke, MD
F. Schuetz, MD
C. Sohn, MD
A. Schneeweiss, MD
Joerg Heil, MD
Publication date: 01-03-2016
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 3/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-015-4918-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

Prognosis of Primary and Recurrent Chondrosarcoma of the Rib

Role of Adjuvant Radiotherapy in Locally Advanced Colonic Carcinoma in the Modern Chemotherapy Era

Distant Metastasis in Colorectal Cancer is a Risk Factor for Anastomotic Leakage

Pushing the Limits of Local Excision for Rectal Cancer: Transanal Minimally Invasive Surgery (TAMIS) for Rectal Cancer Using the Port-in-Port Technique

Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer

Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma